Repository logo
 

DNA damage burden causes selective CUX2 neuron loss in neuroinflammation.

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

Neurodegeneration shows regional and cell-type-specific patterns in ageing and disease1, but the underlying mechanisms for cell-type-specific neuronal losses remain poorly understood. Previous studies have shown that upper cortical layer thinning occurs in progressive human multiple sclerosis (MS) and that cortical layer 2 and layer 3 (L2/3) excitatory neurons (L2/3ENs) that express CUT-like homeobox 2 (CUX2) are selectively vulnerable to degeneration2. Here we report that L2/3ENs within MS cortical lesions have an elevated DNA damage burden. DNA damage and selective loss of L2/3ENs were recapitulated in diverse mouse models of demyelination and pan-cortical inflammation, confirming their intrinsic vulnerability. Functions of Cux2 and activating transcription factor 4 (Atf4) were essential for resilience of L2/3ENs during postnatal neuroinflammation, acting in neurons to enhance DNA double-strand break repair. Interferon-γ, a cytokine implicated in MS pathogenesis3,4, was sufficient to elevate levels of reactive oxygen species, leading to DNA damage-mediated neuronal death in vitro, and caused selective depletion of L2/3 neurons in mice. These findings indicate that DNA damage burden and inadequate repair in CUX2+ L2/3ENs contributes to selective vulnerability in neuroinflammatory injury.

Description

Acknowledgements: We thank D. Clements, L. Elfari and O. Hill for imaging assistance and maintenance; R. Schulte and the staff at the Cambridge Institute for Medical research flow core for flow cytometry sorting; O. B. Faisal for assistance with the Comet assays; the members of the Rowitch, Balmus and Fancy laboratories for comments and suggestions; and A. García for graphics assistance. This work was supported by funding from the European Research Council (Advanced Grant 789054 to D.H.R.; DecOmPress ERC StG, 950584 to L.S.), the Wellcome Trust (to D.H.R.), NIH (P01 NS083513 to D.H.R. and S.P.J.F.; R01NS128021 and R21NS133891 to S.P.J.F.; R01 NS124166 to S.J.F.; R01NS120981 to B.E.; 1R35NS137478 to B.P.), NIHR Cambridge Biomedical Research Centre (NIHR203312 to D.H.R.), Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (to D.H.R., D.G. and B.P.), the US Department of Defence (MS230141 to S.P.J.F.) Alex’s Lemonade Stand Foundation (to S.P.J.F.), Race to Erase MS (to S.P.J.F.), the National MS society (RFA-2203-39300 to L.S.; RG-2001-35775 to B.E.), the German Research Foundation (InCheck GRK 2727, Priority Program SPP 2395, NeuroFlame FOR 5705 to L.S.), the UK Dementia Research Institute (to G.B.), Therapeutic Innovation Networks (PNRR-III-C9-2022-I8 to G.B.), the Hertie Foundation (medMS MyLab, P1180016 to L.S.), an endowment from the Warren family (to B.E.) and a gift from the Spangler Foundation (to S.P.J.F.). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Journal Title

Nature

Conference Name

Journal ISSN

0028-0836
1476-4687

Volume Title

653

Publisher

Springer Nature

Rights and licensing

Except where otherwised noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Sponsorship
European Research Council (789054)
Wellcome Trust (108139/B/15/Z)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF) (Unknown)
Cambridge University Hospitals NHS Foundation Trust (CUH) (Unknown)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF) (R-202206-00503)
ERC